This large retrospective study evaluated the outcomes of selective laser trabeculoplasty.

Allergan’s bimatoprost implant (Durysta) is now the first approved intracameral, sustained-release therapy for lowering IOP in patients with open-angle glaucoma or ocular hypertension.

Weekly case challenge

This study compared the efficacy of a fixed-dose netarsudil/latanoprost combination therapy versus individual monotherapies for open-angle glaucoma and ocular hypertension.

Normal-tension glaucoma (NTG) is an optic neuropathy of unknown etiology characterized by optic disc excavation, retinal nerve fiber layer loss, and visual field defects similar to those seen in other forms of glaucomatous optic neuropathy. Patients with glaucomalike optic nerve and visual field changes yet normal intraocular pressure are numerous and require treatment to preserve vision.

This multicenter trial assessed the ability of phacoemulsification with goniosynechialysis to reduce IOP through 1 year.

This presentation from AGS 2019 discusses trabeculectomy and tube techniques that the presenters have refined and improved on, as well as pearls for these various surgeries.

This presentation from AGS 2019 is a debate among an expert panel on how to treat various cases on glaucoma, the premise being that the physician should limit outside influences that might stop them from providing the same type of care for their patients that they would for a family member.

AbbVie has agreed to acquire Allergan for $63 billion, unlocking key opportunities for growth on both sides of the deal.